Symposia 3 - The WHO System for Reporting Pancreaticobiliary Cytopathology: The Rationale, Structure, Categories and Application

The World Health Organization (WHO), the International Academy of Cytology (IAC) and the and the International Agency for Research on Cancer (IARC) have joined forces to publish a series of cytopathology reporting systems, which will present an international approach to reporting cytopathology of various body sites and mirror the WHO Classification of Tumurs series (with links between the two series). These reporting systems will provide an evidence-based terminology system with associated risk of malignancy and management recommendation per diagnostic category aimed to facilitate diagnosis and patient management. This symposium introduces the Reporting System for Pancreaticobiliary Cytology, which is a revision of the Papanicolaou Society of Cytopathology System of Reporting Pancreaticobiliary Cytology. The WHO System will be described and modifications from the PSC System will be explained. The subsequent case-based seminar will illustrate the application of the WHO System in practice.

Target Audience

This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.

Learning Objectives

  • To introduce the newly proposed international reporting system for pancreaticobiliary cytology
  • To illustrate the changes from the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology
  • To demonstrate the application of The Who System with real cases via a slide seminar
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 Participant
Course opens: 
Course expires: 

Barbara Centeno, MD
Martha Pitman, MD
Michelle Reid, MD, MS
Mauro Saieg, MD, PhD, FIAC
Momin Siddiqui, MD

The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.

The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Lukas Bubendorf, MD, MIAC: Advisory Board - Astra Zeneca, Bayer, Eli Lilly, BMS, Takeda; Research Support - Sanofi, Systems Oncology, Thermo Fisher; Speaker's Fee - Thermo Fisher; Consultant – Systems Oncology, Janssen
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics

The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Kristen A. Atkins, MD, Zubair, Baloch, MD, PhD, Guliz A. Barkan, MD, Christine N. Booth, MD, Leigh Ann Cahill, BS, CT(ASCP)CMIAC, Barbara A. Centeno, MD, Ashish Chandra, MD, FRCPath, DipRCPath (Cytol), Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Andrew Field, MB BS(Hons) FRCPA FIAC DipCytopath(RCPA), Kara L. Hansing, MEd, SCT(ASCP)CM, Lester Layfield, MD, Aparna M Mahajan MD, Sara E. Monaco, MD, Michiya Nishino MD, PhD, N. Paul Ohori MD, Lynnette S. Pineault, MBA, SCT(ASCP), Sinchita Roy-Chowdhuri, MD, PhD, Fernando C. Schmitt, MD, PhD, FIAC, Momin T. Siddiqui, MD, FIAC, Z. Laura Tabatabai, MD, Sana O. Tabbara, MD, Michael J. Thrall, MD, Dena M. Tonkovich, BS, CT(ASCP), Dawn L. Underwood, MS, CT(ASCP), Vivian L. Weiss, MD, PhD, Teresa Wood, MPH, BA, CT(ASCP), Maureen F. Zakowski, MD, JD, Lisa Zhang, MD, Michelle Reid, MD, MS, Mauro Saieg, MD, PhD, FIAC

The ASC staff associated with the development of content for this activity reported no relevant financial relationships.


Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process.  Earn up to 2.0 Credit Hours.

Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians.  The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the States of Florida and California. The credit on each link is good for three years from the live presentation date.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 Participant


Please login or register to take this course.